Spark Ventures

Spark Ventures

04/06/2010 - SPARK Ventures to realise its investment in Complinet | 06/05/2010 - CNBC launches on Livestation | 17/12/2009 - Livestation adds CNN International to its channel offering | IMImobile raises $13m of equity for expansion | 18/09/2009 - Founders of SPARK Ventures’ portfolio company notonthehighstreet.com win ‘Entrepreneur of the Year' | 28/08/2009 - SPARK Ventures realises its investment in Unanimis | 19/06/2009 - Telecom Express and IMImobile join forces to launch IMEXmobile - Mobile Interaction Specialist

SPARK Venture Management
- About SPARK
- Portfolio Investments
  - TMT
  - Healthcare & Life Sciences
- SPARK exits
- SPARK newsroom
- Contact

SPARK Ventures plc
- SPARK Ventures plc portfolio
- Investor relations
- Board of Directors
- Contact

SPARK VCT Funds

Vernalis

Biological therapies:

Celldex Therapeutics, Inc.

Oxford BioMedica plc

Diagnostics & point-of-care:

Oxford Biosensors

Oxford Immunotec

Vivacta Limited

Disease Management & wellness:

Gemini Biomedical

Instrumentation:

IT in Healthcare:

Mirada Solutions

Medical Devices & Medical Technology:

(No investments to date)

Nanotechnology:

Pharmaceuticals and Speciality pharmaceuticals:

Allergy Therapeutics plc

Lectus Therapeutics

Telemedicine & e-Health:

(No investments to date)

Vernalis is a research and development based bio-pharmaceutical company with one marketed product, frovatriptan, six product candidates in clinical trials and a research capability based on structure-based drug discovery technologies.

© 2009 SPARK Ventures |